BioStock: PHI’s CEO comments on the approved US listing

August 21, 2024
Language flag

Phase Holographic Imaging has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.

Read the full interview with Patrik Eschricht on biostock.se.

The dual listing on the OTCQB market represents a significant step in
making PHI’s shares more accessible to US investors. This listing
increases our visibility in the US, aligning with our strategic focus on
expanding into the regenerative medicine market.

Further reading

A hand holding a microphone against a dark background.

Biostock inverview with acting CEO: ”We aim to drive innovation that accelerates breakthroughs in regenerative medicine”

With the introduction of the HoloMonitor CellSync, Phase Holographic Imaging (PHI) leaps forward in live cell imaging technology. Currently in the final stages of development, this next-generation imaging system is undergoing pre-production testing at prestigious U.S. institutions – the Huntsman Cancer Institute and the Wake Forest Institute of Regenerative Medicine. Biostock has interviewed the acting CEO, Ivan Jurković, to learn more.
A journal cover from Advanced Biology with yellow and blue melanocytes and melanoma cells.

Picture-Perfect Science! HoloMonitor® Images Featured on Cover of Advanced Biology

We are proud to announce that a recent study utilizing HoloMonitor® M4 has been featured on the cover of Advanced Biology, Volume 9, Issue 2 (February 2025). The study, led by Dr. Besa Xhabija and colleagues at the University of Michigan-Dearborn, USA, demonstrates the transformative potential of HoloMonitor, our non-invasive, real-time live cell imaging system, in advancing melanoma research.
PHI-global-biostock

BioStock: Kapitalanskaffning ska driva PHI:s globala expansion

PHI genomför just nu en företrädesemission om cirka 64 Mkr. Målet är att öka den globala försäljningen på marknaden för holografisk mikroskopi och icke-invasiv cellanalys. Bolaget, under ledning av nye vd Anders Månsson, fokuserar nu på att öka tillväxttakten väsentligt, vilket underlättas av att man har en färdig produkt inom ett segment som spås växa starkt under kommande år, samt av den större marknadsnärvaro man har möjlighet till genom samarbetet med Altium.
Anders-Mansson-PHI-241209-1046

BioStock: Emission rustar Phase Holographic för internationell satsning (investor pitch)

– Investor pitch – Emissionsaktuella Phase Holographic genomför just nu en fullt ut garanterad företrädesemission om cirka 64 Mkr för att öka sin globala försäljning av produkten HoloMonitor, ett avancerat verktyg för icke-invasiv analys av levande celler. Med en redan färdig produkt som kan positioneras på en globalt växande marknad, siktar man på att öka sin närvaro inom den prekliniska sektorn samtidigt som vägen mot kliniska tillämpningar är utstakad. Vd Anders Månsson besökte BioStocks studie för att berätta mer.
123…10

Latest News

A hand holding a microphone against a dark background.

Biostock inverview with acting CEO: ”We aim to drive innovation that accelerates breakthroughs in regenerative medicine”

With the introduction of the HoloMonitor CellSync, Phase Holographic Imaging (PHI) leaps forward in live cell imaging technology. Currently in the final stages of development, this next-generation imaging system is undergoing pre-production testing at prestigious U.S. institutions – the Huntsman Cancer Institute and the Wake Forest Institute of Regenerative Medicine. Biostock has interviewed the acting CEO, Ivan Jurković, to learn more.
A journal cover from Advanced Biology with yellow and blue melanocytes and melanoma cells.

Picture-Perfect Science! HoloMonitor® Images Featured on Cover of Advanced Biology

We are proud to announce that a recent study utilizing HoloMonitor® M4 has been featured on the cover of Advanced Biology, Volume 9, Issue 2 (February 2025). The study, led by Dr. Besa Xhabija and colleagues at the University of Michigan-Dearborn, USA, demonstrates the transformative potential of HoloMonitor, our non-invasive, real-time live cell imaging system, in advancing melanoma research.
A pen and a calculator placed on top of papers with charts.

Interim Report 3 2024/25

Sales grew significantly for both Q3 and YTD, outperforming the FY results of the previous year. Gross margin continues to be strong, even slightly above planned levels (+4pp). Overall costs remain stable and as per plan, with higher administrative costs due to the capital raise offset by lower R&D expenses. The absolute key to transforming the Company, both short-term and long-term, is a significant increase in sales, which is expected due to a strong pipeline and company potential.
See All News